医学
狭窄
二尖瓣
二尖瓣
心脏病学
内科学
主动脉瓣狭窄
阀门更换
外科
主动脉瓣置换术
冲程(发动机)
主动脉瓣
临床终点
临床试验
机械工程
工程类
作者
Daxin Zhou,Wenzhi Pan,Jianan Wang,Yongjian Wu,Mao Chen,Thomas Modine,Darren Mylotte,N Piazza,Junbo Ge
摘要
Abstract Objective This study reports the 1‐year clinical outcomes of the VitaFlow™ transcatheter aortic valve system in the treatment of severe aortic stenosis. Background The VitaFlow™ system (MicroPort®, Shanghai, China) was developed as a novel transcatheter aortic valve replacement system to mitigate or circumvent some of the challenges associated with heavily calcified valves and bicuspid valves. Methods From September 2014 to November 2017, a prospective, multicenter, single arm study was conducted in 11 centers in China. The primary end point was all cause mortality at 12 months. Results One hundred and ten symptomatic aortic stenosis patients (60 men, 50 women; mean age 77.73 ± 4.78 years) at prohibitive or high risk for surgery were enrolled. Mean society of thoracic surgeons score was 8.84 ± 5.58%. All‐cause mortality was 2.7% at 1‐year. Major stroke, major vascular complication, coronary artery obstruction, new pacemaker implantation occurred in 2.7, 2.7, 1.8, and 19.1% at 1‐year follow‐up, respectively. No patients had moderate or severe paravalvular leak at 1‐year. At 1 year follow‐up, 97% of patients had New York heart association ≤II. Patients with bicuspid valves had similar outcomes as those patients with tricuspid aortic valve stenosis. Conclusions The 12‐month clinical results support the safety and efficacy of VitaFlow™ in the treatment of patients with severe aortic stenosis, including patients with bicuspid aortic valve.
科研通智能强力驱动
Strongly Powered by AbleSci AI